TickerFacts.

Citius Pharmaceuticals, Inc. (CTXR): R&D Expense

Annual figures by period end, from SEC filings.

$9.16M
Year ended 2025-09-30
$5.93M
Trailing 12 months to 2026-06-30
-19.7%
3-year compound annual growth
+0.8%
5-year compound annual growth
+17.7%
10-year compound annual growth
$17.66M2014-09-30: $5742015-09-30: $1.80M2016-09-30: $2.93M2017-09-30: $2.94M2018-09-30: $6.56M2019-09-30: $8.60M2020-09-30: $8.81M2021-09-30: $12.24M2022-09-30: $17.66M2023-09-30: $14.82M2024-09-30: $11.91M2025-09-30: $9.16M$9.16M
2014-09-30 R&D Expense (USD) 2025-09-30
Period endedR&D ExpenseChange YoYSource filing
2025-09-30$9.16M-23.1%2025-12-23, From 2024-10-01
2024-09-30$11.91M-19.7%2025-12-23, From 2023-10-01
2023-09-30$14.82M-16.1%2024-12-27, From 2022-10-01
2022-09-30$17.66M+44.2%2023-12-29, From 2021-10-01
2021-09-30$12.24M+38.9%2022-12-22, From 2020-10-01
2020-09-30$8.81M+2.5%2021-12-15, From 2019-10-01
2019-09-30$8.60M+31.0%2020-12-16, From 2018-10-01
2018-09-30$6.56M+123.5%2019-12-16, From 2017-10-01
2017-09-30$2.94M+0.1%2019-12-16, From 2016-10-01
2016-09-30$2.93M+63.2%2018-12-11, From 2015-10-01
2015-09-30$1.80Mn/m2017-12-13, From 2014-10-01
2014-09-30$574n/a2016-12-23, From 2013-10-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Citius Pharmaceuticals, Inc. (CTXR)2025-09-30$9.16M-23.1%
Silence Therapeutics plc (SLN)2025-12-31$67.75M-0.2%
Acrivon Therapeutics, Inc. (ACRV)2025-12-31$59.99M-6.3%
Zomedica Corp. (ZOMDF)2025-12-31$7.17M-1.4%
Seres Therapeutics, Inc. (MCRB)2025-12-31$49.06M-24.1%
Elite Pharmaceuticals Inc (ELTP)2026-03-31$5.74M-27.9%
Monopar Therapeutics (MNPR)2025-12-31$9.90M-23.8%
Prelude Therapeutics Inc (PRLD)2025-12-31$94.30M-20.1%
Kyntra Bio, Inc. (KYNB)2025-12-31$23.52M-75.4%

Compare CTXR, SLN, ACRV, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗